Loading...
BCR-ABL1 transcript decline ratio combined BCR-ABL1(IS) as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia
Purpose: The early BCR-ABL1 reduction had the prognostic impact of the chronic-phase chronic myeloid leukemia (CML-CP) patients. This study was to find a more precise early prognosis index at 3 months in the patients with newly diagnosed CML-CP, especially for the patients with BCR-ABL1(IS) >10%....
Na minha lista:
| Udgivet i: | J Cancer |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Ivyspring International Publisher
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7052929/ https://ncbi.nlm.nih.gov/pubmed/32127950 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.38752 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|